Jeffrey Humphrey
Net worth: - $ as of 30/03/2024
Network origin in Jeffrey Humphrey first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 14 | |
| Public Company | Biotechnology | 11 | |
Kyowa Kirin Pharmaceutical Development Ltd.
 Kyowa Kirin Pharmaceutical Development Ltd. Miscellaneous Commercial ServicesCommercial Services Kyowa Kirin Pharmaceutical Development Ltd. engages in developing pharmaceutical products. The company was founded on December 31, 1996 and is headquartered in London, the United Kingdom.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
| Extinct | Pharmaceuticals: Major | 1 | |
| Public Company | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Jeffrey Humphrey via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| CELGENE | Biotechnology | Corporate Officer/Principal Public Communications Contact Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
Genzyme Oncology
 Genzyme Oncology Pharmaceuticals: MajorHealth Technology Genzyme Oncology manufactures drugs for cancer therapies. Its products include Campath, B-CLL, and Colar which are used in the treatment of relapsed acute lymphoblastic leukemia in children. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member | |
| ATHIRA PHARMA, INC. | Biotechnology | Director of Finance/CFO | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
 Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC provides legal services. The firm offers services to the communications, education, environmental, health, immigration, public finance, real estate and tax industries. The company was founded in 1933 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Real Estate Development | Corporate Officer/Principal Corporate Officer/Principal | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Undergraduate Degree | |
| Yale University | College/University | Doctorate Degree | |
| New York University | College/University | Graduate Degree Masters Business Admin | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin | |
| University of South Carolina | College/University | Doctorate Degree | |
| Katholieke Universiteit Leuven | College/University | Undergraduate Degree | |
| Budapest University of Technology & Economics | College/University | Graduate Degree | |
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| Waterland Private Equity NV | Investment Managers | Private Equity Investor | |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Boston University School of Law | College/University | Graduate Degree Graduate Degree | |
Cristal Delivery BV
 Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
| JOUNCE THERAPEUTICS, INC. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| IGNYTA INC | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| EDITAS MEDICINE, INC. | Biotechnology | Director/Board Member Chairman | |
| Tufts University School of Medicine | College/University | Corporate Officer/Principal | |
| Mayo Clinic College of Medicine & Science | College/University | Doctorate Degree | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Chief Executive Officer Director/Board Member | |
DROIA NV
 DROIA NV Investment ManagersFinance DROIA NV (DROIA) is an Independent Venture Capital firm founded in 2011 by Bart van Hooland. The firm is headquartered in Meise with additional office in Luxembourg. | Investment Managers | Private Equity Investor | |
Ribon Therapeutics, Inc.
 Ribon Therapeutics, Inc. BiotechnologyHealth Technology Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member Director/Board Member | |
Tusk Therapeutics Ltd.
 Tusk Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Tusk Therapeutics Ltd. operates as a immuno-oncology company, focused on discovering and developing therapeutic antibodies. It provides immune modulating cancer therapeutics. The company is headquartered in Stevenage, the United kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Aadi Subsidiary, Inc.
 Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Biotechnology | Director/Board Member Chief Executive Officer | |
OCTIMET Oncology NV
 OCTIMET Oncology NV BiotechnologyHealth Technology OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands. | Biotechnology | Director/Board Member | |
Highlight Therapeutics SL
 Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Pharmaceuticals: Major | Director/Board Member | |
Convert Pharmaceuticals SA
 Convert Pharmaceuticals SA Miscellaneous Commercial ServicesCommercial Services Convert Pharmaceuticals SA provides preclinical stage drug development services. Its product hypoxia activated prodrug (HAP) is a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. The company was founded by Philippe Lambin, Nicolas Geuens, and Paul Tulcinsky on February 24, 2017 and is headquartered in Liege, Belgium. | Miscellaneous Commercial Services | Chief Executive Officer | |
ArTara Subsidiary, Inc.
 ArTara Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ArTara Subsidiary, Inc. engages in the research and development of specialty diseases therapeutics. Its programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology or gastrointestinal and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chairman Director/Board Member | |
AOBiome Therapeutics, Inc.
 AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Chicago Biomedical Consortium | Director/Board Member | ||
Frontier Medicines Corp.
 Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
Black Belt Therapeutics Ltd.
 Black Belt Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Black Belt Therapeutics Ltd. is a British biotechnology company. | Miscellaneous Commercial Services | Director/Board Member | |
| PROTARA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
| AADI BIOSCIENCE, INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
| New York University School of Medicine | College/University | Doctorate Degree |
Statistics
International
| United States | 36 |
| Belgium | 6 |
| United Kingdom | 3 |
| Switzerland | 2 |
| France | 2 |
Sectoral
| Health Technology | 26 |
| Consumer Services | 13 |
| Commercial Services | 6 |
| Finance | 6 |
Operational
| Director/Board Member | 119 |
| Corporate Officer/Principal | 63 |
| Independent Dir/Board Member | 47 |
| Chief Executive Officer | 26 |
| Chairman | 21 |
Most connected contacts
| Insiders | |
|---|---|
| Scott Braunstein | 25 |
| Alexis Borisy | 25 |
| Emma Reeve | 18 |
| Susan Molineaux | 17 |
| Karen Ho Hong | 16 |
| Richard Levy | 16 |
| Stephen Sands | 15 |
| Andrew Gengos | 15 |
| Mark Goldsmith | 14 |
| Janwillem Naesens | 14 |
| Jigar Raythatha | 13 |
| Adrian Senderowicz | 13 |
| Steven Hoerter | 12 |
| Brendan Delaney | 11 |
| John Thero | 11 |
- Stock Market
- Insiders
- Jeffrey Humphrey
- Company connections
